Schizophrenia

NEI Schizophrenia

NEI Schizophrenia GUIDELINES app brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/364190

Contents of this Issue

Navigation

Page 6 of 19

5 Recommendations for Acute Phase Treatment Î Rapid emergency treatments for acutely psychotic patients showing aggressive behaviors: • Short-acting parenteral antipsychotic with or without parenteral benzodiazepine and with or without parenteral anticholinergic • Rapidly dissolving oral formulations or oral concentrates of atypical antipsychotics Î Use atypical antipsychotics as first-line treatment • Atypical antipsychotics may have superior efficacy for treating cognitive, negative, and affective symptoms • Use lower doses in 1st episode individuals because they are more sensitive to EPS and metabolic side effects • For some patients, conventional antipsychotics may be 1st choice Note: Conventional antipsychotics may be as effective as atypical antipsychotics for acute phase treatment. Î Clozapine should be used in patients with persistent suicidality, violence, or substance abuse Note: Clozapine tends to be under-utilized in some treatment settings, or utilized later than recommended (ie, following multiple antipsychotic treatment failures rather than just two or three). Î Clozapine augmentation with an atypical or a conventional agent or ECT should be preceded by a treatment-refractory evaluation including: Note: Clozapine may also be superior for treatment-resistant symptoms. Î Use long-acting injectable formulations of initial oral medication for patients with adherence issues, violent behavior, or even in early- onset schizophrenia. • Clozapine serum levels • Re-examining diagnosis • Substance abuse • Treatment adherence • Psychosocial stressors

Articles in this issue

Archives of this issue

view archives of Schizophrenia - NEI Schizophrenia